Novartis Sues Aurobindo, Expanding Patent Fight Over Entresto

Novartis said Aurobindo’s proposed generic version of Entresto infringes a patent for the blockbuster treatment for heart failure.

• Novartis is seeking court order blocking copies until patent has expired, according to complaint filed Friday in federal court in Wilmington, Delaware
• Patent is titled “Sacubitril-Valsartan Dosage Regimen for Treating Heart Failure” and was issued July 13, complaint says
  • Patent expires in May 2036: supplemental filing
• Novartis last week expanded legal fight with Crystal, alleging its proposed Entresto copycat infringes two patents that expire in August 2033
• That followed Novartis’s filing in September adding patent that expires in November 2026 to ...